Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G, Karege F 2005. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode
ABSTRACT We had previously reported decreased serum brain-derived neurotrophic factor (BDNF) levels in depressed patients. In the present study, we tested the hypothesis that antidepressant treatment would normalize serum BDNF levels, at least in a subgroup of patients. Major depressed patients (15 females and 11 males) diagnosed according to DSM-IV criteria and healthy controls (13 females and 13 males) participated in this study. Serum BDNF was assayed with the ELISA method for depressed and remitted patients and the severity of depression was evaluated with the Montgomery-Asberg Depression Rating Scale. An analysis of variance showed that treatment had an effect [F(1, 24) = 4.46, p = 0.045] on the normalization of serum BDNF levels. We also found a correlation between the severity of depression (r = 0.51, p = 0.008), the pretreatment BDNF levels (r = 0.62, p = 0.001) and the difference in serum BDNF levels after antidepressant treatment. These results suggest that antidepressant treatment has a positive effect on serum BDNF levels and support the hypothesis of neurotrophic factor involvement in affective disorders.
- SourceAvailable from: Undine E Lang
[Show abstract] [Hide abstract]
- "Upregulation of BDNF may reverse stress-induced deficits in structural and synaptic plasticity in the adult brain, resulting in cognitive flexibility and an increased ability to adapt with environmental challenges that may precipitate or exacerbate depressive episodes. Recent studies demonstrate that BDNF levels are decreased in the blood of depressed patients and its levels are increased with antidepressant treatment (Aydemir et al., 2005; Brunoni et al., 2008; Deuschle et al., 2013; Gervasoni et al., 2005; Karege et al., 2002; Kim et al., 2007; Lee et al., 2006, 2011; Ricken et al., 2013; Sen et al., 2008; Shimizu et al., 2003). Moreover, human BDNF polymorphism and serum levels have been connected with anxiety, risk of depression, neuroticism and serotonergic neurotransmission (Lang et al., 2002; 2004, 2005a, 2005b, 2007, 2009a, 2009b). "
ABSTRACT: Major depression is a common, recurrent mental illness that affects millions of people worldwide. Recently, a unique fast neuroprotective and antidepressant treatment effect has been observed by ketamine, which acts via the glutamatergic system. Hence, a steady accumulation of evidence supporting a role for the excitatory amino acid neurotransmitter (EAA) glutamate in the treatment of depression has been observed in the last years. Emerging evidence indicates that N-methyl-D-aspartate (NMDA), group 1 metabotropic glutamate receptor antagonists and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) agonists have antidepressant properties. Indeed, treatment with NMDA receptor antagonists has shown the ability to sprout new synaptic connections and reverse stress-induced neuronal changes. Based on glutamatergic signaling, a number of therapeutic drugs might gain interest in the future. Several compounds such as ketamine, memantine, amantadine, tianeptine, pioglitazone, riluzole, lamotrigine, AZD6765, magnesium, zinc, guanosine, adenosine aniracetam, traxoprodil (CP-101,606), MK-0657, GLYX-13, NRX-1047, Ro25-6981, LY392098, LY341495, D-cycloserine, D-serine, dextromethorphan, sarcosine, scopolamine, pomaglumetad methionil, LY2140023, LY404039, MGS0039, MPEP, 1-Aminocyclopropanecarboxylic acid all of which target this system have already been brought up, some of them recently. Drugs targeting the glutamatergic system might open up a promising new territory for the development of drugs to meet the needs of patients with major depression. Copyright © 2015. Published by Elsevier Inc.Progress in Neuro-Psychopharmacology and Biological Psychiatry 03/2015; DOI:10.1016/j.pnpbp.2015.02.015 · 4.03 Impact Factor
[Show abstract] [Hide abstract]
- "Logistic regressions were run to examine the relationship between BDNF and remissions status. The model was adjusted for variables (age, gender, smoking, illness duration, antidepressant use, antipsychotic type and dosage) which were previously found to influence serum BDNF levels in an effort to minimise potentially confounding influence (Chen and Huang, 2011; Gervasoni et al., 2005; Green et al., 2011; Nurjono et al., 2012; Trajkovska et al., 2007; Wang et al., 2007; Xiu et al., 2009 "
ABSTRACT: The neurotrophin, brain-derived neurotrophic factor (BDNF), characterises a probable neurobiochemical explanation of maldevelopments in schizophrenia and is a candidate biomarker of the illness. A paucity of studies examining neurobiochemical predictors of remission in schizophrenia exists. In this study, we seek to examine if serum BDNF level is associated with remission status in a sample of Chinese patients with schizophrenia. This study did not find a significant relationship between serum BDNF and remission in patients with schizophrenia. Identification of a suitable biomarker for diagnosis, management, and prognostic outcome is crucial and warrants further study.Psychiatry Research 08/2014; 220(1-2). DOI:10.1016/j.psychres.2014.07.079 · 2.68 Impact Factor
[Show abstract] [Hide abstract]
- "This suggests that rTMS effects on peripheral BDNF levels depend on whether study participants are depressed or not. rTMS may entail both, a decrease of peripheral BDNF in healthy participants with physiological BDNF serum levels and an increase in depressed patients who show a ` priori-reduced BDNF levels (Duman and Monteggia 2006; Gervasoni et al. 2005; Lee et al. 2007). This might indicate a role of BDNF in a negative feedback loop. "
ABSTRACT: Although repetitive transcranial magnetic stimulation (rTMS) is established in the treatment of depression, there is little knowledge about the underlying molecular mechanisms. In the last decade, the neurotrophic hypothesis of depression entailed a plethora of studies on the role of neurogenesis-associated factors in affective disorders and rTMS treatment. In the present study, we hypothesised a sham-controlled increase of peripheral brain-derived neurotrophic factor (BDNF) levels following serial rTMS stimulations in healthy individuals. We investigated the influence of a cycle of nine daily high-frequency (HF)-rTMS (25 Hz) stimulations over the left dorsolateral prefrontal cortex (DLPFC) on serum levels of BDNF in 44 young healthy male volunteers. BDNF serum concentrations were measured at baseline, on day 5 and on day 10. Overall, the statistical analyses showed that the active and sham group differed significantly regarding their responses of BDNF serum levels. Contrary to our expectations, there was a significant decrease of BDNF only during active treatment. Following the treatment period, significantly lower BDNF serum levels were quantified in the active group on day 10, when compared to the sham group. The participants' smoking status affected this effect. Our results suggest that serial HF-rTMS stimulations over the left DLPFC decrease serum BDNF levels in healthy male volunteers. This provides further evidence for an involvement of BDNF in clinical rTMS effects.Journal of Neural Transmission 10/2013; 121(3). DOI:10.1007/s00702-013-1102-1 · 2.87 Impact Factor